Clinical Trials Browser

Phase 1 × INDUSTRY × Panitumumab × Clear all

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT07543744 2026-04-22

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

Phase 1 Recruiting

180 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07094113 2026-02-12

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

434 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT07021898 2025-12-03

BOREALIS-1

Phase 1 Recruiting

200 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1 Active not recruiting

610 enrolled

Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT06983743 2025-09-11

AURORAS-1

Phase 1 Recruiting

200 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06194877 2025-04-20

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

Phase 1 Terminated

13 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05084859 2024-08-09

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT03360734 2021-07-12

GATTO

Phase 1 Completed

50 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT00658658 2016-05-18

Panitumumab in Children With Solid Tumors

Phase 1 Completed

31 enrolled 19 charts

Other solid neoplasm

Solid Tumors

NCT00563316 2016-04-12

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Phase 1 Completed

28 enrolled 11 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00101907 2014-03-20

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Phase 1 Terminated

41 enrolled 17 charts

GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms, Pancreatic Neoplasms

NCT00101894 2012-09-17

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Phase 1 Completed

119 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00091806 2009-07-10

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

86 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

BOREALIS-1

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

AURORAS-1

A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

GATTO

Panitumumab in Children With Solid Tumors

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors